The use of taxanes in early breast cancer

European Journal of Cancer, Supplement

Volumn 1, Issue 7 SPEC. ISS., 2003, Pages 1-10

  Hudis, Clifford ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant chemotherapy; BCIRG 001; CALGB 9344; Neoadjuvant chemotherapy; Taxanes

Indexed keywords

CARBOPLATIN; CIMETIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

AMENORRHEA; ANEMIA; ASTHENIA; BLOOD TOXICITY; BREAST CARCINOMA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DOSE CALCULATION; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EARLY CANCER; FEBRILE NEUTROPENIA; HAZARD ASSESSMENT; HUMAN; MEDICAL ASSESSMENT; NEUROTOXICITY; NEUTROPENIA; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

EID: 5344236018     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)80010-1     Document Type: Article

References (32)

1. Group EBCTC. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med. 333:1995;1444-1455
2. Group EBCT. Ovarian ablation in early breast cancer: overview of the randomized trials. Lancet. 348:1996;1189-1196
3. Group IBCS. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol. 15:1997;1385-1394
4. Group EBCTC. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451
5. Abrams J., Moore T., Friedman M. New chemotherapeutic agents for breast cancer. Cancer. 74:(3 Suppl):1994;1164-1176
6. Huizing M.T., Sewberath M., Pieters R.C., et al. Taxanes: a new class of antitumor agents. Cancer Invest. 13:1995;381-404
7. Rowinsky E.K., Onetto N., Canetta R.M., Arbuck S.G. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol. 19:1992;646-662
8. Hudis C., Seidman A., Baselga J., et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy. J Clin Oncol. 17:1999;93. (abstract)
9. Fornier M.N., Seidman A.D., Theodoulou M., et al. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res. 7:2001;3934-3941
10. Fischer B., Anderson S., Wickerham D., et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol. 15:1997;1858-1869
11. Fisher B., Anderson S., DeCillis A., et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol. 17:1999;3374-3388
12. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 21:2003;976-983
13. Mamounous E.P., Bryant J., Lembersky B.C., et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc Am Soc Clin Oncol. 2003;. abstract 141
14. Adjuvant therapy for breast cancer. NIH Consensus Statement. 17:2000, November 1-3;1-35
15. Nabholtz J., Pienkowski T., Mackey J., et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol. 21:2002;. abstract 141
16. Buzdar A., Singletary S., Valero V., et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 8:2002;1073-1079
17. NSABP. The effect on primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide: preliminary results from NSABP Protocol B-27. Breast Cancer Treatment Reports. 2001;. abstract 5
18. Gianni L., Baselga J., Eiermann W., et al. First report of the European Cooperative Trial in Operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol. 21:2002;. abstract 132
19. Hutcheon A., Heys S., Miller I., et al. Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: a randomized controlled trial. Breast Cancer Treatment Reports. 2001;. abstract 506
20. Norton L., Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Reports. 70:1986;163-169
21. Hudis C., Fornier M., Riccio L., et al. Five-year results of dose-intensive sequential adjuvant chemotherapy for women with high risk node-positive breast cancer: a phase II study. J Clin Oncol. 17:1999;1118-1126
22. Citron M.L., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 21:2003;1431-1439
23. Citron M.L., Berry D.A., Cirrincione C., et al. Superiority of dose-dense over conventional scheduling and equivalence of sequential vs combination adjuvant chemotherapy for node-positive breast cancer (CALGB 9741, INT C9741). San Antonio Breast Cancer Symposium. San Antonio:December 2002;. abstract 15
24. Bonadonna G., Zambetti M., Valagassa P. Sequential or alternating doxorubicin and CMG regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA. 274:1995;796-797
25. Untch M., Konecny G., Ditsch N., et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study. Proc. Am Soc Clin Oncol. 21:2002;. abstract 133
26. Jones S.E., Savin M.A., Asmar L., et al. Three year results of a prospective randomized trial of adjuvant chemotherapy for patients (pts) with stage I-III operable, invasive breast cancer comparing 4 courses of doxorubicin/cyclophosphamide (AC) to 4 courses of docetaxel/cyclophosphamide (TC). Proc Am Soc Clin Oncol. 2003;. abstract 59
27. Seidman A., Hudis C., Albanel J., et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol. 16:1998;3353-3361
28. Winer E., Berry D., Duggan D., Henderson I.C., et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - results from CALGB 9342. Proc Am Soc Clin Oncol. 1998;. abstract
29. Green M., Buzdar A., Smith T., et al. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC - final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol. 21:2002;. abstract 135
30. Seidman A.D., Fornier M.N., Esteva F.J., et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 19:2001;2587-2595
31. Robert N., Leyland-Jones B., Asmar L., et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Treat Reports. 2002;. abstract 35
32. Pusztai L., Ayers M., Simmans F.W., et al. Emerging science: prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc. Am Soc Clin Oncol. 2003;. abstract 1